244 related articles for article (PubMed ID: 22511260)
1. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.
Lopes-Virella MF; Baker NL; Hunt KJ; Lyons TJ; Jenkins AJ; Virella G;
Diabetes Care; 2012 Jun; 35(6):1333-40. PubMed ID: 22511260
[TBL] [Abstract][Full Text] [Related]
2. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.
Lopes-Virella MF; Carter RE; Baker NL; Lachin J; Virella G;
Nephrol Dial Transplant; 2012 Apr; 27(4):1416-23. PubMed ID: 21856760
[TBL] [Abstract][Full Text] [Related]
3. Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.
Hainsworth DP; Gao X; Bebu I; Das A; Olmos de Koo L; Barkmeier AJ; Tamborlane W; Lachin JM; Aiello LP;
Ophthalmology; 2021 Apr; 128(4):554-560. PubMed ID: 32941962
[TBL] [Abstract][Full Text] [Related]
4. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Lachin J; Nathan DM; Virella G;
Diabetes; 2011 Feb; 60(2):582-9. PubMed ID: 20980456
[TBL] [Abstract][Full Text] [Related]
5. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.
Hunt KJ; Baker N; Cleary P; Backlund JY; Lyons T; Jenkins A; Virella G; Lopes-Virella MF;
Atherosclerosis; 2013 Dec; 231(2):315-22. PubMed ID: 24267245
[TBL] [Abstract][Full Text] [Related]
6. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.
Diabetes; 1997 Nov; 46(11):1829-39. PubMed ID: 9356033
[TBL] [Abstract][Full Text] [Related]
7. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.
Lopes-Virella MF; Baker NL; Hunt KJ; Lachin J; Nathan D; Virella G;
Atherosclerosis; 2011 Feb; 214(2):462-7. PubMed ID: 21156319
[TBL] [Abstract][Full Text] [Related]
8. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.
Genuth S; Sun W; Cleary P; Sell DR; Dahms W; Malone J; Sivitz W; Monnier VM;
Diabetes; 2005 Nov; 54(11):3103-11. PubMed ID: 16249432
[TBL] [Abstract][Full Text] [Related]
9. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
10. Oxidized Low-Density Lipoprotein and the Incidence of Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema Determined From Fundus Photographs.
Klein R; Myers CE; Lee KE; Paterson AD; Cruickshanks KJ; Tsai MY; Gangnon RE; Klein BE
JAMA Ophthalmol; 2015 Sep; 133(9):1054-61. PubMed ID: 26181138
[TBL] [Abstract][Full Text] [Related]
11. Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.
; Gubitosi-Klug RA; Sun W; Cleary PA; Braffett BH; Aiello LP; Das A; Tamborlane W; Klein R
JAMA Ophthalmol; 2016 Feb; 134(2):137-45. PubMed ID: 26584339
[TBL] [Abstract][Full Text] [Related]
12. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort.
Lyons TJ; Jenkins AJ; Zheng D; Lackland DT; McGee D; Garvey WT; Klein RL
Invest Ophthalmol Vis Sci; 2004 Mar; 45(3):910-8. PubMed ID: 14985310
[TBL] [Abstract][Full Text] [Related]
13. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.
Diabetes; 1996 Oct; 45(10):1289-98. PubMed ID: 8826962
[TBL] [Abstract][Full Text] [Related]
14. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes.
Monnier VM; Sell DR; Strauch C; Sun W; Lachin JM; Cleary PA; Genuth S;
J Diabetes Complications; 2013; 27(2):141-9. PubMed ID: 23153673
[TBL] [Abstract][Full Text] [Related]
15. Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC.
Monnier VM; Sell DR; Gao X; Genuth SM; Lachin JM; Bebu I;
BMJ Open Diabetes Res Care; 2022 Jan; 10(1):. PubMed ID: 35058313
[TBL] [Abstract][Full Text] [Related]
16. Immune Complexes and the Risk of CVD in Type 1 Diabetes.
Lopes-Virella MF; Bebu I; Hunt KJ; Virella G; Baker NL; Braffett B; Gao X; Lachin JM;
Diabetes; 2019 Sep; 68(9):1853-1860. PubMed ID: 31217176
[TBL] [Abstract][Full Text] [Related]
17. The progression of retinopathy over 2 years: the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study.
Lloyd CE; Klein R; Maser RE; Kuller LH; Becker DJ; Orchard TJ
J Diabetes Complications; 1995; 9(3):140-8. PubMed ID: 7548977
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).
White NH; Cleary PA; Dahms W; Goldstein D; Malone J; Tamborlane WV;
J Pediatr; 2001 Dec; 139(6):804-12. PubMed ID: 11743505
[TBL] [Abstract][Full Text] [Related]
19. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G;
J Diabetes Complications; 2016; 30(4):693-9. PubMed ID: 26861948
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
